Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05571657
Other study ID # MCL10517a
Secondary ID U01IP001093
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date May 12, 2022
Est. completion date December 31, 2022

Study information

Verified date October 2022
Source Marshfield Clinic Research Foundation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A single COVID-19 booster dose has been recommended in the United States for adolescents aged ≥12 years to enhance protection against SARS-CoV-2 infection. This study will assess the efficacy of a one-time reminder/recall for COVID-19 booster dose among eligible adolescents in a regional healthcare system.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 4304
Est. completion date December 31, 2022
Est. primary completion date August 30, 2022
Accepts healthy volunteers No
Gender All
Age group 12 Years to 17 Years
Eligibility Inclusion Criteria: - Marshfield Clinic Health System patient aged 12-17 years with at least one preventive visit or two evaluation & management visits with a Marshfield Clinic Health System provider in the last 36 months - Due for a COVID-19 booster dose (completed the COVID-19 primary series and it has been =5 months since their second dose) Exclusion Criteria: - Primary care provider is not affiliated with Marshfield Clinic Health System - Opted out of Marshfield Clinic Health System centralized vaccine reminder notifications - Received COVID-19 vaccine off label - Missing or invalid contact information - Deceased

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Reminder/Recall Sent Via Preferred Method of Communication
Parents of 12-17 year-old patients due for COVID-19 booster dose will receive a one-time vaccine reminder/recall via the parent's preferred method of communication (mailed letter, text message, email)

Locations

Country Name City State
United States Marshfield Clinic Health System Marshfield Wisconsin

Sponsors (1)

Lead Sponsor Collaborator
Marshfield Clinic Research Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary COVID-19 Booster Dose Number of patients that received a COVID-19 booster dose during follow-up based on electronic health data. Receipt of a COVID-19 booster dose within 90 days of randomization (yes/no) will be assessed using vaccination data available from the Marshfield Clinic Health System (MCHS) electronic health record, which includes vaccinations administered outside of MCHS through data exchanges with the Wisconsin Immunization Registry. Specifically patients will be classified as having received a COVID-19 booster dose if they have record of receipt of COVID-19 booster dose with a vaccination date during the 90-day follow-up period. 90 days
See also
  Status Clinical Trial Phase
Recruiting NCT05918939 - UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study) Early Phase 1
Active, not recruiting NCT06272253 - UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects Early Phase 1
Recruiting NCT05298800 - Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 Phase 4
Recruiting NCT05185817 - Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients Phase 2
Not yet recruiting NCT04876885 - The Future of Viral Communications: Video-Based Health Promotion Strategies for COVID-19 Vaccinations N/A
Completed NCT05373459 - Effect of a Third COVID-19 Booster Among Health Care Workers
Completed NCT04888793 - Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study
Completed NCT04881396 - Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine
Recruiting NCT04871165 - Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals
Active, not recruiting NCT05293665 - Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine Phase 3
Active, not recruiting NCT05405283 - Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults Phase 3
Recruiting NCT05508477 - UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study) Phase 3
Recruiting NCT05471635 - Variables Influencing Anti-COVID-19 Vaccinations Around the World: an Analysis Conducted on Aggregated Data Sourced From Institutional Databases to Understand Whether and How Different Variables Could Affect the Vaccine Coverage (WORLDCOV: Worldwide Determinants of COVID-19 Vaccination)
Recruiting NCT06282692 - INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old Phase 3
Completed NCT05406908 - Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases Phase 4
Recruiting NCT04895007 - Comparative Evaluation of Covid-19 Vaccines Response
Recruiting NCT05831826 - Effectiveness and Safety of the Inactivated COVID-19 Vaccine in Thousands of Patients With Autoimmune Diseases in China
Recruiting NCT05096260 - Getting to Yes, Michigan! (G2YMI) N/A
Completed NCT04962906 - Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes Phase 2
Active, not recruiting NCT05027672 - Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines. Phase 2